与抗糖尿病药物使用模式相关的感染不成比例性分析
Tae Hyeon Kim1,2,3, Kyeongmin Lee2,4, Seoyoung Park2,3
1Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
Scientific reports
|September 29, 2025
概括
与单一治疗相比,抗糖尿病药物组合增加了感染风险. -葡萄糖携运输体-2 (SGLT2) 抑制剂和二乙酶-4 (DPP-4) 抑制剂在单一治疗中表现出特定的感染风险,需要进一步的药物监测.
科学领域:
- 药监和药物安全 药监和药物安全
- 内分泌学和新陈代谢学
- 传染性疾病 传染性疾病
背景情况:
- 不同类型的抗糖尿病药物具有不同的感染风险,但对多种药物治疗方案的证据有限.
- 了解这些风险对于管理糖尿病和预防并发症至关重要.
研究的目的:
- 调查抗糖尿病药物使用与感染风险之间的药监信号.
- 评估抗糖尿病药物使用的数量和模式如何影响感染风险.
主要方法:
- 利用全球药监数据库,将其重组到个人层面.
- 采用多变量后勤回归来估计药监信号,使用调整后报告几率比率 (aROR) 和95%置信区间 (CI).
- 按系统分类感染,并分析药物单一疗法与组合疗法.
主要成果:
- 服用-葡萄糖共运输体-2 (SGLT2) 抑制剂的患者感染频率最高,其次是胰岛素和类似葡萄糖的-1受体激活剂 (GLP-1RA).
- 用SGLT2抑制剂单一治疗与尿路感染有关 (aROR, 10.41),而DPP-4抑制剂与肝胆/胰腺感染有关 (aROR, 1.72).
- 与单一治疗相比,与两种或更多的抗糖尿病药物联合治疗显著增加了感染风险.
结论:
- 感染类型和风险在抗糖尿病药物单一治疗和联合治疗之间有所不同.
- 研究结果强调需要进一步的药物监测,以了解糖尿病患者的感染风险,特别是多药疗法.
- 虽然没有表明因果关系,但该研究确定了需要注意的特定药物感染关联.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
685
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
685
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Diabetes: Symptoms, Diagnosis, and Complications
2.1K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247


